Chemistry:Ibandronic acid
 | |
| Clinical data | |
|---|---|
| Trade names | Boniva, Bonviva, Bondronat, others |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth, intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 0.6% |
| Protein binding | 90.9 to 99.5% (concentration-dependent) |
| Metabolism | Nil |
| Elimination half-life | 10 to 60 hours |
| Excretion | Kidney |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| PDB ligand | |
| Chemical and physical data | |
| Formula | C9H23NO7P2 |
| Molar mass | 319.231 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Ibandronic acid is a bisphosphonate medication used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer.[1] It may also be used to treat hypercalcemia (elevated blood calcium levels). It is typically formulated as its sodium salt ibandronate sodium.
It was patented in 1986 by Boehringer Mannheim and approved for medical use in 1996.[2]
Medical uses
Ibandronate is indicated for the treatment and prevention of osteoporosis in post-menopausal women.[3] In May 2003, the U.S. Food and Drug Administration (FDA) approved Ibandronate as a daily treatment for post-menopausal osteoporosis. The basis for this approval was a three-year, randomized, double-blind, placebo-controlled trial women with post-menopausal osteoporosis. Every participant also received daily oral doses of calcium and 400IUs [international units] of vitamin D. At the study's conclusion, both doses significantly reduced the occurrence risk of new vertebral fractures by 50–52 percent when compared to the effects of the placebo drug.
Ibandronate is efficacious for the prevention of metastasis-related bone fractures in multiple myeloma, breast cancer, and certain other cancers.[4]
Adverse effects
In 2008, the U.S. Food and Drug Administration (FDA) issued a communication warning of the possibility of severe and sometimes incapacitating bone, joint or muscle pain.[5] A study conducted by the American Society of Bone and Mineral Research concluded that long-term use of bisphosphonates, including Boniva, may increase the risk of a rare but serious fracture of the femur. [6] The drug also has been associated with osteonecrosis of the jaw, relatively rare but serious condition.[7]
Pharmacology
| Bisphosphonate | Relative potency |
|---|---|
| Etidronate | 1 |
| Tiludronate | 10 |
| Pamidronate | 100 |
| Alendronate | 100-500 |
| Ibandronate | 500-1000 |
| Risedronate | 1000 |
| Zoledronate | 5000 |
Brand names
Ibandronic acid is marketed under the trade names Boniva in the US, Bondronat in Europe, Bonviva in Asia, Bandrone in India, Ibandrix in Ecuador, Adronil in Pakistan, Bondrova in Bangladesh and Bonprove in Egypt, Fosfonat in Mexico.
References
- ↑ "Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis". Therapeutics and Clinical Risk Management 2 (1): 3–18. March 2006. PMID 18360577.
- ↑ Analogue-based Drug Discovery. John Wiley & Sons. 2006. p. 523. ISBN 9783527607495. https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA523.
- ↑ "Boniva". The American Society of Health-System Pharmacists. https://www.drugs.com/monograph/boniva.html.
- ↑ "Pathogenesis and bisphosphonate treatment of skeletal events and bone pain in metastatic cancer: focus on ibandronate". Onkologie 35 (6): 380–7. 2012. doi:10.1159/000338947. PMID 22722461.
- ↑ "Information for Healthcare Professionals: Bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa)". U.S. Food and Drug Administration. https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124165.htm.
- ↑ "Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research". Journal of Bone and Mineral Research 25 (11): 2267–2294. November 2010. doi:10.1002/jbmr.253. PMID 20842676.; Lay summary in: "JBMR Publishes ASBMR Task Force Report on Atypical Femoral Fractures". Journal of Bone and Mineral Research. 14 September 2010. http://www.asbmr.org/about/pressreleases/detail.aspx?cid=a68f2b70-a117-4094-9f6f-b5993c6a6149.
- ↑ "Osteonecrosis of the jaw (ONJ) and drug treatments for osteoporosis". United Kingdom: The National Osteoporosis Society. https://nos.org.uk/media/1593/k-drug-treatments-for-osteoporosis-osteonecrosis-of-the-jaw-onj-_.pdf.
- ↑ Essentials of Medical Pharmacology (Seventh ed.). New Delhi: Jaypee Brothers Medical Publisher. 2013-09-30. ISBN 9789350259375. OCLC 868299888.
External links
- "Ibandronic acid". Drug Information Portal. U.S. National Library of Medicine. https://druginfo.nlm.nih.gov/drugportal/name/ibandronic%20acid.
 |  |
